WANG Yao-Hui, ZHANG Chong-Yang, SUN Wei, LYU Zhe, LIU Wei-Bin. Effect of Optimized Thrombolysis Treatment Workflow on In-hospital Delay and Prognosis in Acute Mild Ischemic Stroke[J]. Chinese Journal of Stroke, 2019, 14(12): 1205-1208.
[1] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.[2] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志,2015,48(4):246-257.[3] HACKE W,KASTE M,FIESCHI C,et al.Randomised double-blind placebo-controlled trial ofthrombolytic therapy with intravenous alteplase inacute ischaemic stroke(ECASS Ⅱ)[J]. The Lancet,1998,352(9136):1245-1251.[4] FRANK B,GROTTA J C,ALEXANDROV A V,etal. Thrombolysis in stroke despite contraindicationsor warnings?[J]. Stroke,2013,44(3):727-733.[5] KHATRI P,CONAWAY M R,JOHNSTON K C,etal. Ninety-day outcome rates of a prospective cohortof consecutive patients with mild ischemic stroke[J].Stroke,2012,43(2):560-562.[6] LEIRA E C,LUDWIG B R,GUROL M E,et al.The types of neurological deficits might not justifywithholding treatment in patients with low totalNational Institutes of Health Stroke Scale scores[J].Stroke,2012,43(3):782-786.[7] KHATRI P,TAYAMA D,COHEN G,et al. Effectof intravenous recombinant tissue-type plasminogenactivator in patients with mild stroke in the ThirdInternational Stroke Trial-3:post hoc analysis[J].Stroke,2015,46(8):2325-2327.[8] 中国卒中学会科学声明专家组. 急性缺血性卒中静脉溶栓中国卒中学会科学声明[J]. 中国卒中杂志,2017,12(3):267-284.[9] MERETOJA A,KESHTKARAN M,SAVER JL,et al. Stroke thrombolysis:save a minute,save aday[J]. Stroke,2014,45(4):1053-1058.[10] 王耀辉,张重阳,孙伟,等. 基于急救医疗服务的院前干预对急性缺血性脑卒中静脉溶栓门-针时间的影响[J]. 中华危重病急救医学,2018,30(7):667-670.[11] National Institute of Neurological Disordersand Stroke rt-PA Stroke Study Group. Tissueplasminogen activator for acute ischemic stroke[J].N Engl J Med,1995,333(24):1581-1587.[12] SHI L,ZHANG M,LIU H,et al. Safety andoutcome of thrombolysis in mild stroke:a metaanalysis[J/OL]. Med Sci Monit,2014,20:2117-2124.http://doi.org/10.12659/MSM.892259.[13] LOGALLO N,KVISTAD C E,NAESS H,et al.Mild stroke:safety and outcome in patients receivingthrombolysis[J]. Acta Neurol Scand Suppl,2014,129(s198):37-40.[14] 于若梅,曹谡涵,毛保义,等. 重组组织型纤溶酶原激活剂静脉治疗轻型缺血性卒中患者的疗效分析[J]. 中国卒中杂志,2018,13(9):903-907.[15] 张重阳,王耀辉,刘宇鹏,等. 溶栓模式对急性缺血性脑卒中静脉溶栓DNT的影响及效果分析[J]. 中华急诊医学杂志,2019,28(6):755-759.